← Russell 3000 cross-section

CGON CG Oncology, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$6.9bn
Revenue TTM
$6m
Net income TTM
$-224m
Free cash flow
$-179m
Composite score
52.9
Sector rank
#893

Valuation

P / E
EV / EBITDA
EV / sales
950.2
FCF yield
-2.58%
Earnings yield vs 10-yr
-7.96pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3,602.7%
EBITDA margin
-4,008.7%
ROE
-21.8%
ROIC
-6,578.6%
Revenue growth
1,030.3%

Insider activity, last 90 days

Net open-market
$22.00m
Buyers
1
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

During each of the three and six months ended June 30, 2026 and the six months ended June 30, 2025, less than $0.1 million in license and collaboration revenue was recorded related to the Kissei License Agreement. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. …CG Oncology, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →